04:14 PM EST, 02/06/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q4 non-GAAP diluted earnings Thursday of $1.69 per share, up from $1.54 a year earlier.

Analysts polled by FactSet expected $2.03.

Revenue for the quarter ended Dec. 31 was $627.7 million, up from $515.2 million a year earlier.

Analysts surveyed by FactSet expected $629.5 million.

The company said it expects Ingrezza full-year 2025 net product sales of $2.5 billion to $2.6 billion.

Shares of Neurocrine Biosciences ( NBIX ) were down more than 6% in after-hours trading.